No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
VSTM250117P3000
- 0.04
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
0.04Open0.04Pre Close0 Volume13 Open Interest3.00Strike Price0.00Turnover295.06%IV48.34%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.0367Delta0.0343Gamma143.25Leverage Ratio-0.0126Theta0.0000Rho-5.25Eff Leverage0.0006Vega
Intraday
- 5D
- Daily
News
Express News | Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Is Maintained at Outperform by RBC Capital
Verastem Analyst Ratings
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $16
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9